What is growth hormone?
Human growth hormone, or HGH, is a protein hormone made by the pituitary gland. It acts directly on tissues and stimulates production of insulin-like growth factor 1, usually called IGF-1. Together, these signals influence growth, fat use and body composition. Somatropin is a manufactured version of human growth hormone used in prescription medicines such as Genotropin. The Genotropin label describes its approved uses and how it works.
For an adult whose pituitary cannot produce enough growth hormone, replacing it can be useful treatment. A lower hormone level with age, fatigue or difficulty building muscle is a different starting point. Those observations need an explanation before they become a diagnosis.
How is an actual deficiency established?
The clinical history matters. Pituitary disease, surgery, radiation, certain genetic conditions or injury can create a reason to investigate adult growth hormone deficiency. Symptoms alone are too nonspecific. A stimulation test checks how much growth hormone the body can release after a controlled stimulus, rather than relying on one random blood level.
Testing is usually required, but “everyone needs a stimulation test” is too absolute. The prescribing information describes exceptions for congenital or genetic deficiency and for certain patients with several other pituitary hormone deficiencies caused by organic disease. The Endocrine Society guideline also recognizes established childhood genetic or structural causes. An endocrinologist needs to interpret the history, IGF-1 and other hormone results together.
What does replacement change in deficient adults?
The most consistent trial results concern body composition. The Genotropin label summarizes six randomized trials involving 172 adults with deficiency. After six months, treated participants had more lean mass and less body fat than those receiving placebo. Total body water also increased, so a lean-mass change should not automatically be read as new muscle or greater strength.
Newer trials have tested weekly products. In REAL 1, 301 adults were randomized to somapacitan, daily growth hormone or placebo. At 34 weeks, somapacitan reduced the percentage of fat in the trunk by 1.53 percentage points more than placebo and improved visceral fat and lean mass. The trial continued with an extension; its findings apply to diagnosed deficiency.
The foresiGHt trial compared weekly lonapegsomatropin with placebo and daily somatropin. Of 264 randomized participants, 259 received treatment and entered the analysis. At 38 weeks, lonapegsomatropin reduced trunk fat percentage by about 2.04 percentage points more than placebo and increased lean mass. The registry has posted results as well as the published paper.
There are useful limits within those positive findings. In foresiGHt, the proportion reporting a clinically meaningful improvement in the overall symptom and functioning score was numerically higher with lonapegsomatropin, but the difference from placebo was not statistically significant. Some investigators also received delayed alerts about high IGF-1, leading to higher levels than intended. The study was not designed to prove superiority over daily somatropin. Its October 2026 correction fixes baseline pituitary-deficiency descriptions, rather than the treatment-effect estimates.
Clinical guidance supports individualized replacement for benefits that can include body composition, exercise capacity, bone health and quality of life. The response varies. These trials do not establish that treatment extends lifespan, and observational survival comparisons cannot prove that growth hormone itself caused a mortality difference.
What did studies in healthy adults find?
There are human trials outside diagnosed deficiency, and their findings deserve a fair reading. In a six-month trial of 52 healthy men aged 70 to 85, growth hormone increased lean mass and reduced fat. It did not improve the measured strength or endurance outcomes, and side effects were more frequent. That is a body-composition result with a limited practical payoff in that study.
A 2010 trial in 96 recreational athletes found a temporary improvement in sprint capacity of about 3.9% with growth hormone, measured on a cycle test. Strength, jump height and aerobic capacity did not significantly improve. The sprint effect was gone six weeks after treatment stopped, and the lean-mass increase was largely extracellular water. The trial was too small to establish safety or the significance of the result for competitive sport.
A 16-week study in 122 older men also reported gains in body composition and muscle performance, with some outcomes appearing greater when growth hormone was added. Every group received testosterone during suppression of natural testosterone production, so this was a combined-hormone experiment. It cannot establish what growth hormone alone would do. Blood pressure rose across the treatment groups.
These findings do not support saying growth hormone has never improved any performance measure. They also do not show that it reverses aging, prevents disability or adds healthy years of life. Those are larger questions than a change on a scan or a short exercise test.
Which products are approved, and what needs monitoring?
In the United States, daily somatropin products such as Genotropin and weekly Sogroya (somapacitan) and Skytrofa (lonapegsomatropin) have adult growth hormone deficiency indications. Skytrofa’s adult indication was added in July 2025. Somapacitan is a modified growth hormone, while lonapegsomatropin releases somatropin over time. Their dosing and the timing of blood tests are product-specific. Other approved uses depend on the particular product and age group.
The labels describe fluid retention, joint or muscle symptoms, carpal tunnel symptoms and impaired glucose tolerance or diabetes. Active malignancy and certain acute critical illnesses are contraindications. Thyroid and adrenal replacement may also need reassessment in someone with pituitary disease. Monitoring looks at symptoms and adverse effects as well as IGF-1 and glucose; keeping a laboratory value in range does not remove every risk.
There is a specific U.S. legal restriction as well. FDA’s current HGH import alert states that anti-aging, bodybuilding and athletic enhancement are not approved uses, and that distribution, or possession with intent to distribute, for these uses violates federal law. It also warns about counterfeit and unapproved products. These are U.S. statements, not a claim that prescribing rules are identical in every country.
What is worth discussing with an endocrinologist?
Potential benefit
- Replacement has demonstrated body-composition benefits in adults with confirmed deficiency.
- Some people also improve in function or quality of life, with the response assessed individually.
Important limits
- A scan showing more lean mass does not establish more strength or longer life.
- Weekly products still require monitoring and can cause adverse effects.
Useful questions
- What established the diagnosis, and were other explanations considered?
- Which outcome should improve, how will it be measured, and what would prompt a change or stop?
If deficiency is not established, a growth hormone secretagogue is not an automatic substitute. For example, tesamorelin has a specific HIV-associated lipodystrophy indication. The evidence for one hormone or one diagnosis does not transfer to every compound that raises GH or IGF-1.
Where the evidence applies
Diagnosed deficiency
Placebo-controlled trials support replacement effects, particularly on body composition.
Healthy older adults
Small trials show body-composition changes, with mixed functional findings and adverse effects.
Athletic performance
One trial found a temporary sprint-capacity gain, without improvement in the other performance tests.
Longer-term questions
The trials discussed here do not establish an anti-aging or lifespan benefit.
Questions people ask
Can a low IGF-1 result diagnose growth hormone deficiency?
A single result usually cannot settle the diagnosis. An endocrinologist considers pituitary history, other hormone deficiencies and an appropriate stimulation test. Some established genetic or structural causes and combinations of pituitary deficiencies are exceptions to repeat stimulation testing.
Does more lean mass mean more muscle strength?
Not necessarily. Lean-mass measurements include body water as well as muscle. In the recreational-athlete trial, the increase in lean mass was largely explained by extracellular water. Sprint capacity improved temporarily, while the other tested performance measures did not.
Is a weekly product the same as daily somatropin?
The products share a treatment goal in diagnosed deficiency, but their molecules, delivery and dosing differ. Somapacitan is a modified growth hormone; lonapegsomatropin releases somatropin over time. Product choice, switching and the timing of IGF-1 testing require the prescribing clinician’s instructions.
Can HGH be prescribed for anti-aging in the United States?
HGH is not FDA approved for anti-aging, bodybuilding or athletic enhancement. FDA states that distributing it, or possessing it with intent to distribute, for these uses violates the specific federal restrictions on HGH. A prescription does not turn an unapproved anti-aging use into an approved indication.
What to take away
- A proper diagnosis determines whether replacement evidence applies.
- Daily and weekly products have demonstrated benefits and product-specific risks.
- Positive body-composition or short-term performance findings do not establish rejuvenation.
The evidence
Selected original studies, trial records and official prescribing information. See the Science library for related research.
Sources and U.S. regulatory information checked November 9, 2026.
This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. Approval and clinical use depend on the specific product, indication and jurisdiction. Any treatment decision should be made with a qualified physician. Individual results vary.